BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A, Ghobrial RM. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Current Oncology 2022;29:4267-4273. [DOI: 10.3390/curroncol29060341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lominadze Z, Hill K, Shaik MR, Canakis JP, Bourmaf M, Adams-mardi C, Abutaleb A, Mishra L, Shetty K. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. IJMS 2023;24:2358. [DOI: 10.3390/ijms24032358] [Reference Citation Analysis]
2 Woo SM, Kimchy AV, Sequeira LM, Dorris CS, He AR, Rangnekar AS. Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. Curr Oncol 2022;29:9813-25. [PMID: 36547185 DOI: 10.3390/curroncol29120771] [Reference Citation Analysis]
3 Zhang Y, Esmail A, Mazzaferro V, Abdelrahim M. Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. Cancers 2022;14:5074. [DOI: 10.3390/cancers14205074] [Reference Citation Analysis]
4 Tanaka T, Takata K, Yokoyama K, Fukuda H, Yamauchi R, Fukunaga A, Shakado S, Sakisaka S, Hirai F. Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology 2022;29:4799-4810. [DOI: 10.3390/curroncol29070381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]